AblaCare is developing a minimally invasive approach for the treatment of polycystic ovary syndrome (PCOS) related infertility.
PCOS is one of the most common female endocrine disorder (up to 10% of women are thought to be affected) and is thought to be the leading cause of female infertility caused by ovulatory dysfunction, accounting for up to 75% of such dysfunction. While effective, current treatments for PCOs are associated with significant risks and side effects: 1st-line drug-based treatment raises the risk of multiple pregnancies and has common side effects and resistance (up to 40%), 2nd-line surgical ovarian drilling (tissue ablation) has limited clinical adoption due to invasiveness, and 3rd-line IVF is costly, highly "medicalised", and often associated with a higher risk of multiple pregnancies.
The AblaCare approach would replicate the well-established success of the surgical ovarian drilling approach (80% patients resume ovulation in 3 months, and 60% are pregnant within 6 months), whilst being less invasive and less risky than current solutions, providing patients with a more natural and less medicalised pregnancy experience.
AblaCare is currently recruiting patients in its feasibility clinical trial.